Latka logo

How Oxford Drug Design CEO Graham Richards grew Oxford Drug Design to $2.7M revenue with a 11 person team in 2024.

InhibOx is a pioneer in the development and application of new technologies to drive drug discovery. Their multidisciplinary research team has brought together breakthroughs in computational chemistry, cheminformatics, mathematics, cloud computing and software-as-a-service (SaaS) delivery methods to create DrugFinder: the next generation drug discovery platform.

Last updated

Oxford Drug Design Revenue

In 2024, Oxford Drug Design's revenue reached $2.7M. The company previously reported $1.4M in 2023. Since its launch in 2001, Oxford Drug Design has shown consistent revenue growth.

Oxford Drug Design Revenue GrowthReported revenue / ARR by year$0$600K$1M$2M$2M$3M2001200320052007200920112013201520172019202120232024$0$1M$3MSource: GetLatka.com
YearMilestone
2024Oxford Drug Design Hit $2.7m revenue in October 2024
2023Oxford Drug Design Hit $1.4m revenue in November 2023
2022Oxford Drug Design Hit $1.1m revenue in November 2022
2022Oxford Drug Design Hit $1.1m revenue in May 2022
2021Oxford Drug Design Hit $709.9k revenue in November 2021
2021Oxford Drug Design Hit $709.9k revenue in April 2021
2001Launched with $0 revenue

Oxford Drug Design Valuation, Funding Rounds

Oxford Drug Design has not publicly disclosed its valuation. The company has raised $12.4M in total funding to date.

Oxford Drug Design has raised $12.4M in total funding across 5 rounds, most recently a $2.7M Convertible Note round in 2022.

Oxford Drug Design Capital Raised & ValuationCumulative capital raised and post-money valuation by roundCapital raised (cum.)Valuation$0$3M$6M$9M$12M$15M2001200320052007200920112013201520172019202120222001 cumulative: $0 • 2001 Founded: $02006 cumulative: $2M • 2001 Founded: $0 • 2006 Venture Round: $2M2017 cumulative: $4M • 2001 Founded: $0 • 2006 Venture Round: $2M • 2017 Series A: $1M2019 cumulative: $7M • 2001 Founded: $0 • 2006 Venture Round: $2M • 2017 Series A: $1M • 2019 Grant: $3M2019 cumulative: $10M • 2001 Founded: $0 • 2006 Venture Round: $2M • 2017 Series A: $1M • 2019 Grant: $3M • 2019 Venture Round: $3M2022 cumulative: $12M • 2001 Founded: $0 • 2006 Venture Round: $2M • 2017 Series A: $1M • 2019 Grant: $3M • 2019 Venture Round: $3M • 2022 Convertible Note: $3M$12M2001 Founded: $0 valuationSource: GetLatka.com
YearRoundAmountValuation% Sold
2022Convertible Note$2.7M--
2019Venture Round$2.7M--
2019Grant$3.2M--
2017Series A$1.2M--
2006Venture Round$2.4M--

Oxford Drug Design Employees & Team Size

Oxford Drug Design employs approximately 11 people as of 2026.

Oxford Drug Design has 11 total employees in different roles and functions.

Oxford Drug Design Team GrowthReported headcount over time06121824302001200320052007200920112013201520172019202120232024001111Source: GetLatka.com
YearMilestone
2024Reached 11 employees (October 2024)
2023Reached 11 employees (November 2023)
2022Reached 9 employees (November 2022)
2022Reached 9 employees (May 2022)
2021Reached 7 employees (November 2021)
2021Reached 25 employees (April 2021)
2020Reached 7 employees (November 2020)

Founder / CEO

Graham Richards

Graham Richards is listed as Founder / CEO at Oxford Drug Design.

Q&A

QuestionAnswer
What's your age?-
Favorite online tool?-
Favorite book?-
Favorite CEO?-
Advice for 20 year old self-

Customers

We do not have customer count information for Oxford Drug Design yet.

Frequently Asked Questions about Oxford Drug Design

What is Oxford Drug Design's revenue?

Oxford Drug Design generates $2.7M in revenue.

Who founded Oxford Drug Design?

Oxford Drug Design was founded by Graham Richards.

Who is the CEO of Oxford Drug Design?

The CEO of Oxford Drug Design is Graham Richards.

How much funding does Oxford Drug Design have?

Oxford Drug Design raised $12.4M.

How many employees does Oxford Drug Design have?

Oxford Drug Design has 11 employees.

Where is Oxford Drug Design headquarters?

Oxford Drug Design is headquartered in Oxford, United Kingdom.

People Also Viewed

NextME logo

NextME

NextME makes it simple for businesses to manage waitlists and serve more customers. Track visits and wait times, engage your customers in real-time with a custom virtual waiting room, and grow your business like never before. NextME leverages proprietary historical data to help businesses quote more accurate wait times during peak hours. We believe in superior customer service and that waiting in line can be done virtually, not physically. NextME's digital waitlist for businesses is available to download in the App Store today: http://apple.co/1IUTQWw We're hiring! See our current opening positions here: https://bit.ly/3llzOho Need an extra hand with a product demo? Give us a call at (877) 639-8631

BluAgent logo

BluAgent

BluAgent Technologies is a fully integrated SaaS platform that streamlines and simplify the entire safety and compliance process

Digital Horizon logo

Digital Horizon

Digital Horizon is a VC firm focused on backing exceptional entrepreneurs building B2B software-based solutions and marketplaces. With a presence in London, Tel Aviv and Moscow, Digital Horizon aims to seek out early-stage technology companies with the ultimate goal to assist them in building and scaling their business.

Trefis logo

Trefis

Provider of a business analysis technology. The company provides a data analytics technology for investors and decision-makers in business that allows users to share, use, and collaborate on analysis.

Liquid Logics logo

Liquid Logics

Liquid Logics, a True cloud-based SaaS Full Cycle Lending Software Solution for the residential Mortgage banking Industry. Based in the greater Kansas City area, Liquid Logics developed a full cycle Loan creation, Automated Underwriting and Mortgage Brief Case empowering borrower transparency and direct control of the loan process, changing their experience the way Travelocity did to the travel market. Liquid Logics unlike other legacy Loan Origination System who promise future roadmaps for online systems, provides today, online secure products that are focused on allowing consumers and lenders to effectively self-manage the flow of information and bi-directional direct communication between all interested parties of the transaction on all platform mobile, PC or tablets. The suite of products will provide real efficiency and profitability while gaining a competitive advantage. For more information please visit liquidlogics.com or contact us directly at 816-295-6240

DCatalog logo

DCatalog

DCatalog is the leading technology provider of digital publishing solutions. Our technology allows you to convert your PDFs into a unique digital content experience. Our suite of innovative digital publishing software solutions leverage a cloud based platform allowing you to deliver content via the web, tablets, mobile devices, and social channels. The elite features of DCatalog surpass any other software solution in the publishing industry. How It Works: DCatalog will convert PDFs and other printed materials into online and offline customized digital editions. Customizations include the ability to personally brand the content with a logo, embed unlimited video and audio, translate into various languages, track analytics, and sell products from within the edition, plus a whole lot more. DCatalog publishing solutions allow many brands worldwide to create digital editions in minutes, including digital catalogs, brochures, magazines and more. We are always willing to create custom solutions to serve the unique needs of every client. Our publishing solutions help clients reduce costs, expand reach, and improve effectiveness, while providing readers with a media-rich, visually stimulating digital content experience. Since the business was founded in 2008, DCatalog has experienced rapid growth as a privately held company headquartered in the capital of innovation, Silicon Valley.

Compare Oxford Drug Design to the industry

Oxford Drug Design operates across multiple industries. Browse revenue, funding, and growth data for Oxford Drug Design in each sector below.

Source Attribution

Source: all data was collected from GetLatka company research and founder interviews. Revenue, funding, team, and customer figures are presented as company-reported or GetLatka-estimated metrics where the profile data identifies them that way.

Company data last updated .

Oxford Drug Design Revenue 2024: $2.7M ARR, $12.4M Raised